Adoptive T-cell therapy with CD45RA-deplected donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients
Yuste JR (1,2), Díaz de Cerio AL (3,4), Rifón J (4), Moreno C (3), Panizo M (1), Inogés S (3,4).
(1) Division of Infectious Diseases, Clínica Universidad de Navarra, Pamplona, Spain.
(2) Department of Internal Medicine, Clínica Universidad de Navarra, Pamplona, Spain.
(3) Immunology and Immuotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain.
(4) Hematology Service and Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
Cytomegalovirus (CMV) infections can induce severe complications in immunosuppressed patients. Currently, ganciclovir represents the preferred treatment option; however, in patients with resistance or toxicity related to ganciclovir, the therapeutic options are limited.Cellular immunity plays an important role in the control of viral infections.
Adoptive T cell therapy can contribute to recovering immunological function in immunosuppressed patients. Selective T cell depletion targeting CD45RA enhances early T cell recovery and can represent a salvage therapy.
In this study, an immunocompromised non-transplanted patient with CMV disease and toxicity to conventional therapy was successfully treated by adoptive transfer of CD45RA-depleted T cells.
CITATION Antivir Ther. 2019 Mar 26. doi: 10.3851/IMP3307